MA30667B1 - Procedes therapeutiques pour traiter des troubles vasculaires de l'oeil par des antagonistes de dll4. - Google Patents
Procedes therapeutiques pour traiter des troubles vasculaires de l'oeil par des antagonistes de dll4.Info
- Publication number
- MA30667B1 MA30667B1 MA31667A MA31667A MA30667B1 MA 30667 B1 MA30667 B1 MA 30667B1 MA 31667 A MA31667 A MA 31667A MA 31667 A MA31667 A MA 31667A MA 30667 B1 MA30667 B1 MA 30667B1
- Authority
- MA
- Morocco
- Prior art keywords
- ischemic
- dii4
- retinopathy
- organs
- tissues
- Prior art date
Links
- 208000019553 vascular disease Diseases 0.000 title abstract 3
- 238000002560 therapeutic procedure Methods 0.000 title abstract 2
- 102100033553 Delta-like protein 4 Human genes 0.000 title 1
- 101000872077 Homo sapiens Delta-like protein 4 Proteins 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 230000000302 ischemic effect Effects 0.000 abstract 4
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 210000000056 organ Anatomy 0.000 abstract 2
- 238000002054 transplantation Methods 0.000 abstract 2
- 206010059245 Angiopathy Diseases 0.000 abstract 1
- 208000031104 Arterial Occlusive disease Diseases 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 201000006474 Brain Ischemia Diseases 0.000 abstract 1
- 206010008120 Cerebral ischaemia Diseases 0.000 abstract 1
- 208000005590 Choroidal Neovascularization Diseases 0.000 abstract 1
- 206010060823 Choroidal neovascularisation Diseases 0.000 abstract 1
- 206010055665 Corneal neovascularisation Diseases 0.000 abstract 1
- 206010012689 Diabetic retinopathy Diseases 0.000 abstract 1
- 208000010412 Glaucoma Diseases 0.000 abstract 1
- 102000005650 Notch Receptors Human genes 0.000 abstract 1
- 108010070047 Notch Receptors Proteins 0.000 abstract 1
- 206010035138 Placental insufficiency Diseases 0.000 abstract 1
- 208000017442 Retinal disease Diseases 0.000 abstract 1
- 206010038923 Retinopathy Diseases 0.000 abstract 1
- 206010038933 Retinopathy of prematurity Diseases 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 208000021328 arterial occlusion Diseases 0.000 abstract 1
- 210000001367 artery Anatomy 0.000 abstract 1
- 206010008118 cerebral infarction Diseases 0.000 abstract 1
- 201000000159 corneal neovascularization Diseases 0.000 abstract 1
- 230000007850 degeneration Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 208000037906 ischaemic injury Diseases 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 230000036244 malformation Effects 0.000 abstract 1
- 208000031225 myocardial ischemia Diseases 0.000 abstract 1
- 201000003142 neovascular glaucoma Diseases 0.000 abstract 1
- 208000002815 pulmonary hypertension Diseases 0.000 abstract 1
- 238000011084 recovery Methods 0.000 abstract 1
- 230000002207 retinal effect Effects 0.000 abstract 1
- 230000009885 systemic effect Effects 0.000 abstract 1
- 208000037905 systemic hypertension Diseases 0.000 abstract 1
- 210000003462 vein Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1891—Angiogenesic factors; Angiogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/515—Angiogenesic factors; Angiogenin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Marine Sciences & Fisheries (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Toxicology (AREA)
- Dermatology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Un procédé thérapeutique pour traiter les désordres ischémiques ou vasculaires par l'administrant d'un agent capable d'empêcher l'activité delta-like humaine du ligand 4 (DII4) à un sujet ayant besoin. Préférablement, l'agent est un anticorps anti-DII4 ou un fragment de l'anticorps capable d'empêcher l'attache du DII4 à un récepteur Notch. Dans une incorporation, le désordre ischémique ou vasculaire est les blessures ischémiques, l'ischémie cérébrale, l'ischémie cardiaque, les conditions ischémiques affectant les membres et les autres organes ou tissus, les malformations artérielles veineuses, le rétablissement des blessures, la transplantation d'organes ou de tissus, l'insuffisance placentaire, le rétrécissement et l'occlusion artérielle, l'athérosclérose, et l'hypertension systémique ou pulmonaire. Dans une autre incorporation, la maladie traitée est une maladie ou une condition d'oeil telle que la rétinopathie de la prématurité, la rétinopathie ischémique et l'occlusion rétinienne des veines ou d'artères, la rétinopathie diabétique, la néovascularisation choroïde, la dégénération maculaire relative à l'âge, la néovascularisation cornéenne, le glaucome néovasculaire ou la transplantation cornéenne.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83600306P | 2006-08-07 | 2006-08-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA30667B1 true MA30667B1 (fr) | 2009-08-03 |
Family
ID=38904599
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA31667A MA30667B1 (fr) | 2006-08-07 | 2009-02-26 | Procedes therapeutiques pour traiter des troubles vasculaires de l'oeil par des antagonistes de dll4. |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US20080181893A1 (fr) |
| EP (1) | EP2054082B1 (fr) |
| JP (1) | JP5529536B2 (fr) |
| KR (1) | KR101497355B1 (fr) |
| CN (1) | CN101500605B (fr) |
| AU (1) | AU2007281916B2 (fr) |
| BR (1) | BRPI0716424B8 (fr) |
| CA (1) | CA2660235C (fr) |
| CO (1) | CO6150190A2 (fr) |
| CR (1) | CR10627A (fr) |
| DK (1) | DK2054082T3 (fr) |
| ES (1) | ES2398253T3 (fr) |
| GT (1) | GT200900029A (fr) |
| HR (1) | HRP20130271T1 (fr) |
| IL (1) | IL196612A (fr) |
| MA (1) | MA30667B1 (fr) |
| ME (1) | ME00591A (fr) |
| MX (1) | MX2009000674A (fr) |
| MY (1) | MY150092A (fr) |
| NO (1) | NO341857B1 (fr) |
| NZ (1) | NZ574794A (fr) |
| PL (1) | PL2054082T3 (fr) |
| PT (1) | PT2054082E (fr) |
| RS (1) | RS52685B (fr) |
| RU (1) | RU2429876C2 (fr) |
| SG (1) | SG174033A1 (fr) |
| SI (1) | SI2054082T1 (fr) |
| SV (1) | SV2009003161A (fr) |
| TN (1) | TN2009000036A1 (fr) |
| UA (1) | UA95304C2 (fr) |
| WO (1) | WO2008019144A2 (fr) |
| ZA (1) | ZA200900337B (fr) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2066694T1 (sl) | 2006-09-29 | 2016-02-29 | Oncomed Pharmaceuticals, Inc. | Sestavki in postopki za diagnosticiranje in zdravljenje raka |
| JP2010517944A (ja) * | 2007-01-26 | 2010-05-27 | バイオインヴェント インターナショナル アーベー | Ｄｌｌ４シグナリング阻害薬およびその使用 |
| GB0709333D0 (en) * | 2007-05-15 | 2007-06-20 | Smart Targeting Ltd | Binding protein |
| CN102149728B (zh) * | 2008-09-10 | 2014-10-15 | 霍夫曼-拉罗奇有限公司 | 抑制眼部血管生成的方法 |
| CA2735900A1 (fr) * | 2008-09-19 | 2010-03-25 | Medimmune, Llc | Anticorps diriges contre dll4 et leurs utilisations |
| CA2742969A1 (fr) | 2008-11-07 | 2010-05-14 | Fabrus Llc | Anticorps anti-dll4 et utilisations associees |
| WO2011008641A1 (fr) | 2009-07-13 | 2011-01-20 | Beth Israel Deaconess Medical Center, Inc. | Méthodes de modulation de langiogenèse et traitement de maladies associées à langiogenèse |
| CA2771575A1 (fr) | 2009-08-29 | 2011-03-03 | Abbott Laboratories | Proteines therapeutiques se liant a dll4 |
| UY32920A (es) * | 2009-10-02 | 2011-04-29 | Boehringer Ingelheim Int | Moleculas de unión biespecíficas para la terapia anti-angiogénesis |
| TR201818814T4 (tr) * | 2009-10-16 | 2019-01-21 | Oncomed Pharm Inc | Dll4 antagonist antikorlarının ve anti-hipertansif ajanların terapötik kombinasyonu ve kullanımı. |
| JO3183B1 (ar) | 2010-01-29 | 2018-03-08 | Regeneron Pharma | طرق لمعالجة أمراض المناعة الذاتية مضادات dll4 |
| CA2791631A1 (fr) * | 2010-03-02 | 2011-09-09 | Abbvie Inc. | Proteines therapeutiques de liaison a dll4 |
| US8551479B2 (en) | 2010-09-10 | 2013-10-08 | Oncomed Pharmaceuticals, Inc. | Methods for treating melanoma |
| US9527925B2 (en) | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
| PT3485903T (pt) | 2011-09-23 | 2023-02-17 | Mereo Biopharma 5 Inc | Agentes de ligação a vegf/dll4 e utilizações dos mesmos |
| EP2906295A4 (fr) * | 2012-10-15 | 2016-06-01 | Oncomed Pharm Inc | Méthodes de traitement de maladies oculaires |
| CA2889638A1 (fr) | 2012-10-31 | 2014-05-08 | Oncomed Pharmaceuticals, Inc. | Methodes et surveillance d'un traitement par un antagoniste de dll4 |
| US9931199B2 (en) * | 2014-05-05 | 2018-04-03 | Roberto Gustavo ALBERTAZZI | Methods and apparatus for treating keratoconus |
| ES2808153T3 (es) | 2014-10-31 | 2021-02-25 | Mereo Biopharma 5 Inc | Terapia de combinación para tratamiento de enfermedad |
| AU2016326609B2 (en) | 2015-09-23 | 2023-03-09 | Mereo Biopharma 5, Inc. | Methods and compositions for treatment of cancer |
| WO2018094267A1 (fr) * | 2016-11-17 | 2018-05-24 | Children's Medical Center Corporation | Nouveaux procédés pour améliorer la prise de greffe microvasculaire de tissus biotechniques et primaires |
| EP4417619A4 (fr) | 2021-10-12 | 2025-12-03 | Palmira Biopharma Llc | Séquence nucléotidique codant une protéine de fusion |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7306799B2 (en) * | 1999-06-08 | 2007-12-11 | Regeneron Pharmaceuticals, Inc. | Use of VEGF inhibitors for treatment of eye disorders |
| US20060134121A1 (en) | 2004-10-29 | 2006-06-22 | Gavin Thurston | DII4 antagonists, assays, and therapeutic methods thereof |
| US20070213266A1 (en) * | 2005-09-01 | 2007-09-13 | Vasgene Therapeutics, Inc. | Methods for using and identifying modulators of Delta-like 4 |
| CA2654304A1 (fr) | 2006-06-06 | 2007-12-13 | Genentech, Inc. | Compositions et procedes destines a moduler le developpement vasculaire |
-
2007
- 2007-08-07 MX MX2009000674A patent/MX2009000674A/es active IP Right Grant
- 2007-08-07 AU AU2007281916A patent/AU2007281916B2/en active Active
- 2007-08-07 ME MEP-31/09A patent/ME00591A/xx unknown
- 2007-08-07 KR KR1020097004668A patent/KR101497355B1/ko active Active
- 2007-08-07 PT PT78111374T patent/PT2054082E/pt unknown
- 2007-08-07 SI SI200731170T patent/SI2054082T1/sl unknown
- 2007-08-07 MY MYPI20090335A patent/MY150092A/en unknown
- 2007-08-07 CN CN200780029497.8A patent/CN101500605B/zh active Active
- 2007-08-07 DK DK07811137.4T patent/DK2054082T3/da active
- 2007-08-07 UA UAA200902033A patent/UA95304C2/ru unknown
- 2007-08-07 JP JP2009523820A patent/JP5529536B2/ja active Active
- 2007-08-07 US US11/890,741 patent/US20080181893A1/en not_active Abandoned
- 2007-08-07 CA CA2660235A patent/CA2660235C/fr active Active
- 2007-08-07 RS RS20130078A patent/RS52685B/sr unknown
- 2007-08-07 RU RU2009107921/15A patent/RU2429876C2/ru active
- 2007-08-07 PL PL07811137T patent/PL2054082T3/pl unknown
- 2007-08-07 SG SG2011055829A patent/SG174033A1/en unknown
- 2007-08-07 WO PCT/US2007/017546 patent/WO2008019144A2/fr not_active Ceased
- 2007-08-07 EP EP07811137A patent/EP2054082B1/fr active Active
- 2007-08-07 BR BRPI0716424A patent/BRPI0716424B8/pt active IP Right Grant
- 2007-08-07 ES ES07811137T patent/ES2398253T3/es active Active
- 2007-08-07 HR HRP20130271TT patent/HRP20130271T1/hr unknown
- 2007-08-07 NZ NZ574794A patent/NZ574794A/en unknown
-
2009
- 2009-01-15 ZA ZA2009/00337A patent/ZA200900337B/en unknown
- 2009-01-20 IL IL196612A patent/IL196612A/en active IP Right Grant
- 2009-02-03 TN TN2009000036A patent/TN2009000036A1/fr unknown
- 2009-02-05 SV SV2009003161A patent/SV2009003161A/es unknown
- 2009-02-06 GT GT200900029A patent/GT200900029A/es unknown
- 2009-02-20 CR CR10627A patent/CR10627A/es unknown
- 2009-02-26 MA MA31667A patent/MA30667B1/fr unknown
- 2009-03-04 NO NO20090984A patent/NO341857B1/no unknown
- 2009-03-05 CO CO09022898A patent/CO6150190A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA30667B1 (fr) | Procedes therapeutiques pour traiter des troubles vasculaires de l'oeil par des antagonistes de dll4. | |
| Brown et al. | Congenital retinal macrovessels | |
| Papadopoulou et al. | Intravitreal ranibizumab may induce retinal arteriolar vasoconstriction in patients with neovascular age-related macular degeneration | |
| Ozdemir et al. | Regression of serous macular detachment after intravitreal triamcinolone acetonide in patients with diabetic macular edema | |
| Lee et al. | Short-term changes of intraocular pressure and ocular perfusion pressure after intravitreal injection of bevacizumab or ranibizumab | |
| Drance et al. | Comparison of the effect of latanoprost 0.005% and timolol 0.5% on the calculated ocular perfusion pressure in patients with normal-tension glaucoma | |
| Amselem et al. | Intravitreal bevacizumab (Avastin) injection in ocular ischemic syndrome | |
| Hosseini et al. | Effect of intravitreal bevacizumab on retrobulbar blood flow in injected and uninjected fellow eyes of patients with neovascular age-related macular degeneration | |
| Chen et al. | Treatment of branch retinal vein occlusion induced macular edema in treatment-naive cases with a single intravitreal triamcinolone or bevacizumab injection | |
| Iyer et al. | Chronic ocular small vessel disease: An overview of diabetic retinopathy and its relationship with cardiovascular health | |
| An et al. | Neovascular glaucoma due to branch retinal vein occlusion combined with branch retinal artery occlusion | |
| Giuffrè et al. | The effects of 2% ibopamine eye drops on the intraocular pressure and pupil motility of patients with open-angle glaucoma | |
| Lung et al. | Influence of infusion volume on the ocular hemodynamic effects of peribulbar anesthesia | |
| ES2324200T3 (es) | Medicamentos oftalmologicos retino-protectores, que comprenden ramipril o ramiprilato. | |
| Froehler et al. | Angiographic investigation of orbital vascular variations in the rabbit and implications for endovascular intra-arterial chemotherapy models | |
| Stefánsson | Diabetic macular edema | |
| RU2229863C2 (ru) | Способ лечения ишемических заболеваний глаз | |
| Kayikcioglu et al. | Miliary microemboli of the retinal arterioles and choriocapillaris after subcutaneous injection of triamcinolone acetonide | |
| Cohen et al. | Selective thrombolysis performed through meningo-ophthalmic artery in central retinal artery occlusion | |
| Eris et al. | Early retinal and choroidal effect of photodynamic treatment in patients with polypoidal choroidal vasculopathy with or without anti-vascular endothelial growth factor: An optical coherence tomography angiography study | |
| ES2275933T3 (es) | Tratamiento de enfermedades oftalmologicas neovasculares. | |
| Hayreh et al. | Retinal hemorrhages in malignant arterial hypertension | |
| Maher et al. | Intraoperative lidocaine injection into the carotid sinus during endarterectomy | |
| CY1113840T1 (el) | Χρηση ανταγωνιστων d114 σε ισχαιμικη βλαβη ή αγγειακη ανεπαρκεια | |
| Jalalova et al. | METHOD OF TREATMENT OF ISCHEMIC CONDITIONS OF THE OPTIC NERVE AND RETINA (LITERATURE REVIEW) |